Department of Pharmacy, King Hussein Cancer Center, Queen Rania Al-Abdallah StreetPO Box 1269, Amman, 11941, Jordan.
Department of Health Services Research, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Support Care Cancer. 2022 Dec;30(12):10099-10109. doi: 10.1007/s00520-022-07392-w. Epub 2022 Oct 10.
Sepsis is a common complication in patients with cancer, but studies evaluating the outcomes of critically ill cancer patients with sepsis on a global scale are limited. We aimed to summarize the existing evidence on mortality rates in this patient population.
Prospective and retrospective observational studies evaluating critically ill adult cancer patients with sepsis, severe sepsis, and/or septic shock were included. Studies published from January 2010 to September 2021 that reported at least one mortality outcome were retrieved from MEDLINE (Ovid), Embase (Ovid), and Cochrane databases. Study selection, bias assessment, and data collection were performed independently by two reviewers, and any discrepancies were resolved by a third reviewer. The risk of bias was assessed using the Newcastle-Ottawa scale. We calculated pooled intensive care unit (ICU), hospital, and 28/30-day mortality rates. The heterogeneity of the data was tested using the chi-square test, with a P value < 0.10 indicating significant heterogeneity.
A total of 5464 citations were reviewed, of which 10 studies met the inclusion criteria; these studies included 6605 patients. All studies had a Newcastle-Ottawa scale score of 7 or higher. The mean patient age ranged from 51.4 to 64.9 years. The pooled ICU, hospital, and 28/30 day mortality rates were 48% (95% CI, 43- 53%; I = 80.6%), 62% (95% CI, 58-67%; I = 0%), and 50% (95% CI, 38- 62%; I = 98%), respectively. Substantial between-study heterogeneity was observed.
Critically ill cancer patients with sepsis had poor survival, with a hospital mortality rate of about two-thirds. The substantial observed heterogeneity among studies could be attributed to variability in the criteria used to define sepsis as well as variability in treatment, the severity of illness, and care across settings. Our results are a call to action to identify strategies that improve outcomes for cancer patients with sepsis.
脓毒症是癌症患者的常见并发症,但在全球范围内评估危重症癌症合并脓毒症患者结局的研究有限。本研究旨在总结该人群死亡率的现有证据。
纳入评估危重症成年癌症合并脓毒症、严重脓毒症和/或脓毒性休克患者的前瞻性和回顾性观察性研究。从 MEDLINE(Ovid)、Embase(Ovid)和 Cochrane 数据库中检索 2010 年 1 月至 2021 年 9 月发表的至少报告 1 项死亡率结局的研究。由 2 名评审员独立进行研究选择、偏倚评估和数据采集,任何分歧均由第 3 名评审员解决。使用 Newcastle-Ottawa 量表评估偏倚风险。我们计算了 ICU、医院和 28/30 天死亡率的汇总数据。使用卡方检验测试数据的异质性,P 值<0.10 表示存在显著异质性。
共评价了 5464 篇引文,其中 10 项研究符合纳入标准,共纳入 6605 例患者。所有研究的 Newcastle-Ottawa 量表评分均为 7 分或以上。患者的平均年龄为 51.464.9 岁。汇总的 ICU、医院和 28/30 天死亡率分别为 48%(95%CI,4353%;I=80.6%)、62%(95%CI,5867%;I=0%)和 50%(95%CI,3862%;I=98%)。研究间存在显著的异质性。
合并脓毒症的危重症癌症患者的生存率较差,院内死亡率约为三分之二。研究间观察到的显著异质性可能归因于脓毒症定义标准的差异以及治疗、疾病严重程度和各医疗机构间护理的差异。我们的研究结果呼吁采取行动,确定改善脓毒症癌症患者结局的策略。